Pseudoxanthomonas winnipegensis is a newly described bacterial species, mainly found in patients with cystic fibrosis in Canada. The bacteria were recovered from 10 patients over seven years from various sources such as ear, throat, dialysate, and sinus specimens. The patients ranged in age from 2 months to 84 years and included five males and five females from two provinces. The prevalence of P. winnipegensis in other regions and populations are unknown, and more studies are needed to determine its distribution, diversity, and pathogenicity.
Despite its novelty, Pseudoxanthomonas winnipegensis has not caused any significant infections or complications in the patients it has been isolated from. It is susceptible to most antibiotics, and no outbreaks or endemics have been reported so far. However, the bacteria’s potential emergence and spread in human and animal hosts cannot be ruled out, as its epidemiology is not well understood.
The bacteria may be present in environmental sources, such as water, plants, or contaminated soils, as suggested by the origin of other Pseudoxanthomonas species. However, no environmental isolates of P. winnipegensis have been reported yet. As such, more research is needed to monitor and understand the epidemiology of this emerging bacterial species. Overall, the study by Bernard et al. (2020) highlights the need for increased surveillance and characterization of bacterial pathogens to prepare public health systems better and prevent potential outbreaks.
Classification and Structure:
Kingdom: Bacteria
Phylum: Pseudomonadota
Class: Gammaproteobacteria
Order: Xanthomonadales
Family: Xanthomonadaceae
Genus:Pseudoxanthomonas
Species:P. winnipegensis
Pseudoxanthomonas winnipegensis is a gram-negative bacillus with a yellowish pigment, forming convex colonies that are beige in color. It has a medium length, curved, and asporogenous structure. Its genome is circular in structure and spans between 4.36 to 4.73 Mb, with a G+C content of 69.12 mol%. It has 4,505,034 bases and 4,077 coding sequences.
Antigenic Types:
Pseudoxanthomonas winnipegensis is divided into two antigenic types, A and B, based on the serological reactions of its O-antigen with specific antisera. Antigenic type A is more common and includes the type strain NML 130738, while antigenic type B is rare and includes only one strain, NML 171591. The T6SS of P. winnipegensis has been identified to be active and is responsible for mediating interbacterial competition.
Additionally, Pseudoxanthomonas capsules can also act as antigens and elicit an immune response or as adhesins and mediate the attachment to host cells or surfaces. These characteristics convey essential information about the biology and pathogenic potential of P. winnipegensis and provide insight into the mechanisms of bacterial competition and virulence.
Pathogenesis:
Pseudoxanthomonas winnipegensis is a rare and newly discovered bacterium that has been isolated from a few human cases and environmental samples. The exact mode of transmission of P. winnipegensis is still unknown, but it may be acquired from environmental sources such as water, plants, or contaminated soils. It may also be transmitted from infected individuals, medical devices, or procedures such as catheterization or surgery. The bacterium has been isolated from various clinical sources, such as ear and throat samples, dialysate, and sinus specimens, indicating its potential ability to cause respiratory infections and other complications.
Pseudoxanthomonas winnipegensis obtained its name from Canada, Winnipeg, Manitoba, where the species strains were characterized. The bacterium has also been recovered from human clinical materials, especially from patients with cystic fibrosis, who have impaired mucociliary clearance and chronic inflammation of the lungs. This raises concerns about the potential pathogenesis of P. winnipegensis in susceptible individuals.
Currently, the pathogenesis of P. winnipegensis in humans needs to be better understood. However, the bacterium’s ability to adhere to host cells and evade host defenses may play a role in its pathogenesis. More research is needed to understand the virulence factors and pathogenic mechanisms.
Host Defenses:
The human host defenses against P. winnipegensis in cystic fibrosis include both innate and adaptive immune responses. Innate immune responses, such as mucociliary clearance, antimicrobial peptides, and phagocytes, are impaired or dysregulated by abnormal CFTR function and persistent bacterial colonization. This forms a vicious cycle of infection and inflammation that worsens the disease.
Complement may be effective against P. winnipegensis, which has a high G+C content in its genome and may be susceptible to complement-mediated damage. Antimicrobial peptides may also be effective against P. winnipegensis, as they have a yellowish pigment that may indicate the presence of carotenoids, which are known to increase the susceptibility of bacteria to antimicrobial peptides.
Adaptive immune responses, such as antibodies and T cells, can further defend against P. winnipegensis. Helper T cells can stimulate B cells to produce antibodies, activate macrophages to enhance phagocytosis, and recruit other inflammatory cells to the infection site. Humoral immunity is essential for preventing bacterial colonization & invasion of mucosal surfaces, like the respiratory tract, which is often affected by cystic fibrosis.
Moreover, humoral immunity may be effective against P. winnipegensis as it has a unique 16S rRNA gene sequence that may serve as a target for antibody recognition. By activating both innate & adaptive immune responses, human host defenses can counteract the harmful effects of P. winnipegensis in cystic fibrosis and prevent disease progression.
Clinical manifestations:
Pseudoxanthomonas winnipegensis is a bacterial species that has been isolated from various sources, including ear and throat samples from patients with cystic fibrosis, ear infections, dialysate, and sinus specimens. This bacterium is known to cause opportunistic infections in immunocompromised or chronically ill patients, particularly those with cystic fibrosis.
Clinical manifestations of P. winnipegensis varies depending on the source of infection. It can cause ear infections, dialysate infections, and sinus infections. Patients with cystic fibrosis are mainly vulnerable and might experience more severe symptoms. It is mandatory for healthcare providers to be aware of the potential for P. winnipegensis infections in these patients and to take appropriate measures to prevent and treat such infections.
Diagnosis:
To diagnose Pseudoxanthomonas winnipegensis, several tests can be performed. These tests include:
Gram Staining: This test is used to differentiate between gram-positive and gram-negative bacteria. P. winnipegensis is a gram-negative bacterium, so that it will stain pink under the microscope.
Oxidase Test: It detects the presence of cytochrome c oxidase, an enzyme that catalyzes the transfer of electrons from a donor to oxygen. P. winnipegensis is oxidase-positive, so it will turn the reagent dark purple or blue.
Carbohydrate Fermentation Test: This test determines the ability of bacteria to ferment various carbohydrates and produce acid or gas. P. winnipegensis can ferment glucose, lactose, sucrose, maltose, and fructose so that the broth will turn yellow, and gas will be produced for these carbohydrates.
16S rRNA Gene Sequencing: This test analyzes the sequence of the 16S ribosomal RNA gene, which is highly conserved among bacteria and can be used to identify and classify them. This method can be used to identify and classify Pseudoxanthomonas winnipegensis.
Other tests to diagnose P. winnipegensis include whole genome sequencing, MALDI-TOF mass spectrometry, cellular fatty acid analysis, and antimicrobial susceptibility testing.
Control:
Washing hands frequently, covering sneezes & coughs, and avoiding contact with sick people can prevent the spread of the bacterium.
Following the prescribed treatment regimen for cystic fibrosis: This includes taking medications, doing chest physiotherapy, and having regular check-ups to maintain optimal lung function and reduce the risk of bacterial infections.
Seeking medical attention if symptoms of infection occur: This can help diagnose and treat the infection early, reducing the risk of complications.
Avoiding exposure to contaminated water, soil, or plants: This includes avoiding activities such as swimming, drinking untreated water, or gardening in contaminated soil where the bacterium may be present.
In healthcare settings, additional control measures may be necessary, including appropriate sterilization and disinfection of medical equipment, proper hand hygiene practices, and following infection prevention and control protocols.
»
Home » Pathogen » Pseudoxanthomonas winnipegensis
Pseudoxanthomonas winnipegensis
Updated :
November 11, 2023
Epidemiology:
Pseudoxanthomonas winnipegensis is a newly described bacterial species, mainly found in patients with cystic fibrosis in Canada. The bacteria were recovered from 10 patients over seven years from various sources such as ear, throat, dialysate, and sinus specimens. The patients ranged in age from 2 months to 84 years and included five males and five females from two provinces. The prevalence of P. winnipegensis in other regions and populations are unknown, and more studies are needed to determine its distribution, diversity, and pathogenicity.
Despite its novelty, Pseudoxanthomonas winnipegensis has not caused any significant infections or complications in the patients it has been isolated from. It is susceptible to most antibiotics, and no outbreaks or endemics have been reported so far. However, the bacteria’s potential emergence and spread in human and animal hosts cannot be ruled out, as its epidemiology is not well understood.
The bacteria may be present in environmental sources, such as water, plants, or contaminated soils, as suggested by the origin of other Pseudoxanthomonas species. However, no environmental isolates of P. winnipegensis have been reported yet. As such, more research is needed to monitor and understand the epidemiology of this emerging bacterial species. Overall, the study by Bernard et al. (2020) highlights the need for increased surveillance and characterization of bacterial pathogens to prepare public health systems better and prevent potential outbreaks.
Classification and Structure:
Kingdom: Bacteria
Phylum: Pseudomonadota
Class: Gammaproteobacteria
Order: Xanthomonadales
Family: Xanthomonadaceae
Genus:Pseudoxanthomonas
Species:P. winnipegensis
Pseudoxanthomonas winnipegensis is a gram-negative bacillus with a yellowish pigment, forming convex colonies that are beige in color. It has a medium length, curved, and asporogenous structure. Its genome is circular in structure and spans between 4.36 to 4.73 Mb, with a G+C content of 69.12 mol%. It has 4,505,034 bases and 4,077 coding sequences.
Antigenic Types:
Pseudoxanthomonas winnipegensis is divided into two antigenic types, A and B, based on the serological reactions of its O-antigen with specific antisera. Antigenic type A is more common and includes the type strain NML 130738, while antigenic type B is rare and includes only one strain, NML 171591. The T6SS of P. winnipegensis has been identified to be active and is responsible for mediating interbacterial competition.
Additionally, Pseudoxanthomonas capsules can also act as antigens and elicit an immune response or as adhesins and mediate the attachment to host cells or surfaces. These characteristics convey essential information about the biology and pathogenic potential of P. winnipegensis and provide insight into the mechanisms of bacterial competition and virulence.
Pathogenesis:
Pseudoxanthomonas winnipegensis is a rare and newly discovered bacterium that has been isolated from a few human cases and environmental samples. The exact mode of transmission of P. winnipegensis is still unknown, but it may be acquired from environmental sources such as water, plants, or contaminated soils. It may also be transmitted from infected individuals, medical devices, or procedures such as catheterization or surgery. The bacterium has been isolated from various clinical sources, such as ear and throat samples, dialysate, and sinus specimens, indicating its potential ability to cause respiratory infections and other complications.
Pseudoxanthomonas winnipegensis obtained its name from Canada, Winnipeg, Manitoba, where the species strains were characterized. The bacterium has also been recovered from human clinical materials, especially from patients with cystic fibrosis, who have impaired mucociliary clearance and chronic inflammation of the lungs. This raises concerns about the potential pathogenesis of P. winnipegensis in susceptible individuals.
Currently, the pathogenesis of P. winnipegensis in humans needs to be better understood. However, the bacterium’s ability to adhere to host cells and evade host defenses may play a role in its pathogenesis. More research is needed to understand the virulence factors and pathogenic mechanisms.
Host Defenses:
The human host defenses against P. winnipegensis in cystic fibrosis include both innate and adaptive immune responses. Innate immune responses, such as mucociliary clearance, antimicrobial peptides, and phagocytes, are impaired or dysregulated by abnormal CFTR function and persistent bacterial colonization. This forms a vicious cycle of infection and inflammation that worsens the disease.
Complement may be effective against P. winnipegensis, which has a high G+C content in its genome and may be susceptible to complement-mediated damage. Antimicrobial peptides may also be effective against P. winnipegensis, as they have a yellowish pigment that may indicate the presence of carotenoids, which are known to increase the susceptibility of bacteria to antimicrobial peptides.
Adaptive immune responses, such as antibodies and T cells, can further defend against P. winnipegensis. Helper T cells can stimulate B cells to produce antibodies, activate macrophages to enhance phagocytosis, and recruit other inflammatory cells to the infection site. Humoral immunity is essential for preventing bacterial colonization & invasion of mucosal surfaces, like the respiratory tract, which is often affected by cystic fibrosis.
Moreover, humoral immunity may be effective against P. winnipegensis as it has a unique 16S rRNA gene sequence that may serve as a target for antibody recognition. By activating both innate & adaptive immune responses, human host defenses can counteract the harmful effects of P. winnipegensis in cystic fibrosis and prevent disease progression.
Clinical manifestations:
Pseudoxanthomonas winnipegensis is a bacterial species that has been isolated from various sources, including ear and throat samples from patients with cystic fibrosis, ear infections, dialysate, and sinus specimens. This bacterium is known to cause opportunistic infections in immunocompromised or chronically ill patients, particularly those with cystic fibrosis.
Clinical manifestations of P. winnipegensis varies depending on the source of infection. It can cause ear infections, dialysate infections, and sinus infections. Patients with cystic fibrosis are mainly vulnerable and might experience more severe symptoms. It is mandatory for healthcare providers to be aware of the potential for P. winnipegensis infections in these patients and to take appropriate measures to prevent and treat such infections.
Diagnosis:
To diagnose Pseudoxanthomonas winnipegensis, several tests can be performed. These tests include:
Gram Staining: This test is used to differentiate between gram-positive and gram-negative bacteria. P. winnipegensis is a gram-negative bacterium, so that it will stain pink under the microscope.
Oxidase Test: It detects the presence of cytochrome c oxidase, an enzyme that catalyzes the transfer of electrons from a donor to oxygen. P. winnipegensis is oxidase-positive, so it will turn the reagent dark purple or blue.
Carbohydrate Fermentation Test: This test determines the ability of bacteria to ferment various carbohydrates and produce acid or gas. P. winnipegensis can ferment glucose, lactose, sucrose, maltose, and fructose so that the broth will turn yellow, and gas will be produced for these carbohydrates.
16S rRNA Gene Sequencing: This test analyzes the sequence of the 16S ribosomal RNA gene, which is highly conserved among bacteria and can be used to identify and classify them. This method can be used to identify and classify Pseudoxanthomonas winnipegensis.
Other tests to diagnose P. winnipegensis include whole genome sequencing, MALDI-TOF mass spectrometry, cellular fatty acid analysis, and antimicrobial susceptibility testing.
Control:
Washing hands frequently, covering sneezes & coughs, and avoiding contact with sick people can prevent the spread of the bacterium.
Following the prescribed treatment regimen for cystic fibrosis: This includes taking medications, doing chest physiotherapy, and having regular check-ups to maintain optimal lung function and reduce the risk of bacterial infections.
Seeking medical attention if symptoms of infection occur: This can help diagnose and treat the infection early, reducing the risk of complications.
Avoiding exposure to contaminated water, soil, or plants: This includes avoiding activities such as swimming, drinking untreated water, or gardening in contaminated soil where the bacterium may be present.
In healthcare settings, additional control measures may be necessary, including appropriate sterilization and disinfection of medical equipment, proper hand hygiene practices, and following infection prevention and control protocols.
Pseudoxanthomonas winnipegensis is a newly described bacterial species, mainly found in patients with cystic fibrosis in Canada. The bacteria were recovered from 10 patients over seven years from various sources such as ear, throat, dialysate, and sinus specimens. The patients ranged in age from 2 months to 84 years and included five males and five females from two provinces. The prevalence of P. winnipegensis in other regions and populations are unknown, and more studies are needed to determine its distribution, diversity, and pathogenicity.
Despite its novelty, Pseudoxanthomonas winnipegensis has not caused any significant infections or complications in the patients it has been isolated from. It is susceptible to most antibiotics, and no outbreaks or endemics have been reported so far. However, the bacteria’s potential emergence and spread in human and animal hosts cannot be ruled out, as its epidemiology is not well understood.
The bacteria may be present in environmental sources, such as water, plants, or contaminated soils, as suggested by the origin of other Pseudoxanthomonas species. However, no environmental isolates of P. winnipegensis have been reported yet. As such, more research is needed to monitor and understand the epidemiology of this emerging bacterial species. Overall, the study by Bernard et al. (2020) highlights the need for increased surveillance and characterization of bacterial pathogens to prepare public health systems better and prevent potential outbreaks.
Classification and Structure:
Kingdom: Bacteria
Phylum: Pseudomonadota
Class: Gammaproteobacteria
Order: Xanthomonadales
Family: Xanthomonadaceae
Genus:Pseudoxanthomonas
Species:P. winnipegensis
Pseudoxanthomonas winnipegensis is a gram-negative bacillus with a yellowish pigment, forming convex colonies that are beige in color. It has a medium length, curved, and asporogenous structure. Its genome is circular in structure and spans between 4.36 to 4.73 Mb, with a G+C content of 69.12 mol%. It has 4,505,034 bases and 4,077 coding sequences.
Antigenic Types:
Pseudoxanthomonas winnipegensis is divided into two antigenic types, A and B, based on the serological reactions of its O-antigen with specific antisera. Antigenic type A is more common and includes the type strain NML 130738, while antigenic type B is rare and includes only one strain, NML 171591. The T6SS of P. winnipegensis has been identified to be active and is responsible for mediating interbacterial competition.
Additionally, Pseudoxanthomonas capsules can also act as antigens and elicit an immune response or as adhesins and mediate the attachment to host cells or surfaces. These characteristics convey essential information about the biology and pathogenic potential of P. winnipegensis and provide insight into the mechanisms of bacterial competition and virulence.
Pathogenesis:
Pseudoxanthomonas winnipegensis is a rare and newly discovered bacterium that has been isolated from a few human cases and environmental samples. The exact mode of transmission of P. winnipegensis is still unknown, but it may be acquired from environmental sources such as water, plants, or contaminated soils. It may also be transmitted from infected individuals, medical devices, or procedures such as catheterization or surgery. The bacterium has been isolated from various clinical sources, such as ear and throat samples, dialysate, and sinus specimens, indicating its potential ability to cause respiratory infections and other complications.
Pseudoxanthomonas winnipegensis obtained its name from Canada, Winnipeg, Manitoba, where the species strains were characterized. The bacterium has also been recovered from human clinical materials, especially from patients with cystic fibrosis, who have impaired mucociliary clearance and chronic inflammation of the lungs. This raises concerns about the potential pathogenesis of P. winnipegensis in susceptible individuals.
Currently, the pathogenesis of P. winnipegensis in humans needs to be better understood. However, the bacterium’s ability to adhere to host cells and evade host defenses may play a role in its pathogenesis. More research is needed to understand the virulence factors and pathogenic mechanisms.
Host Defenses:
The human host defenses against P. winnipegensis in cystic fibrosis include both innate and adaptive immune responses. Innate immune responses, such as mucociliary clearance, antimicrobial peptides, and phagocytes, are impaired or dysregulated by abnormal CFTR function and persistent bacterial colonization. This forms a vicious cycle of infection and inflammation that worsens the disease.
Complement may be effective against P. winnipegensis, which has a high G+C content in its genome and may be susceptible to complement-mediated damage. Antimicrobial peptides may also be effective against P. winnipegensis, as they have a yellowish pigment that may indicate the presence of carotenoids, which are known to increase the susceptibility of bacteria to antimicrobial peptides.
Adaptive immune responses, such as antibodies and T cells, can further defend against P. winnipegensis. Helper T cells can stimulate B cells to produce antibodies, activate macrophages to enhance phagocytosis, and recruit other inflammatory cells to the infection site. Humoral immunity is essential for preventing bacterial colonization & invasion of mucosal surfaces, like the respiratory tract, which is often affected by cystic fibrosis.
Moreover, humoral immunity may be effective against P. winnipegensis as it has a unique 16S rRNA gene sequence that may serve as a target for antibody recognition. By activating both innate & adaptive immune responses, human host defenses can counteract the harmful effects of P. winnipegensis in cystic fibrosis and prevent disease progression.
Clinical manifestations:
Pseudoxanthomonas winnipegensis is a bacterial species that has been isolated from various sources, including ear and throat samples from patients with cystic fibrosis, ear infections, dialysate, and sinus specimens. This bacterium is known to cause opportunistic infections in immunocompromised or chronically ill patients, particularly those with cystic fibrosis.
Clinical manifestations of P. winnipegensis varies depending on the source of infection. It can cause ear infections, dialysate infections, and sinus infections. Patients with cystic fibrosis are mainly vulnerable and might experience more severe symptoms. It is mandatory for healthcare providers to be aware of the potential for P. winnipegensis infections in these patients and to take appropriate measures to prevent and treat such infections.
Diagnosis:
To diagnose Pseudoxanthomonas winnipegensis, several tests can be performed. These tests include:
Gram Staining: This test is used to differentiate between gram-positive and gram-negative bacteria. P. winnipegensis is a gram-negative bacterium, so that it will stain pink under the microscope.
Oxidase Test: It detects the presence of cytochrome c oxidase, an enzyme that catalyzes the transfer of electrons from a donor to oxygen. P. winnipegensis is oxidase-positive, so it will turn the reagent dark purple or blue.
Carbohydrate Fermentation Test: This test determines the ability of bacteria to ferment various carbohydrates and produce acid or gas. P. winnipegensis can ferment glucose, lactose, sucrose, maltose, and fructose so that the broth will turn yellow, and gas will be produced for these carbohydrates.
16S rRNA Gene Sequencing: This test analyzes the sequence of the 16S ribosomal RNA gene, which is highly conserved among bacteria and can be used to identify and classify them. This method can be used to identify and classify Pseudoxanthomonas winnipegensis.
Other tests to diagnose P. winnipegensis include whole genome sequencing, MALDI-TOF mass spectrometry, cellular fatty acid analysis, and antimicrobial susceptibility testing.
Control:
Washing hands frequently, covering sneezes & coughs, and avoiding contact with sick people can prevent the spread of the bacterium.
Following the prescribed treatment regimen for cystic fibrosis: This includes taking medications, doing chest physiotherapy, and having regular check-ups to maintain optimal lung function and reduce the risk of bacterial infections.
Seeking medical attention if symptoms of infection occur: This can help diagnose and treat the infection early, reducing the risk of complications.
Avoiding exposure to contaminated water, soil, or plants: This includes avoiding activities such as swimming, drinking untreated water, or gardening in contaminated soil where the bacterium may be present.
In healthcare settings, additional control measures may be necessary, including appropriate sterilization and disinfection of medical equipment, proper hand hygiene practices, and following infection prevention and control protocols.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
